Clinical reference Biomarker Directory
Back to directory

MUC1

Established

MUC1 underlies CA 15-3/CA 27.29, breast cancer markers used for monitoring, not screening or diagnosis.

Also known as MUC1 CA 15-3 CA 27.29
In plain language

MUC1 is the gene behind two related blood tests used to monitor breast cancer treatment and watch for it coming back — not to screen for or diagnose the cancer in the first place.

Biomarker & context

MUC1 is a mucin gene whose protein product underlies CA 15-3 and CA 27.29, two related tumor markers used in breast cancer management.

What it indicates

Elevated CA 15-3/CA 27.29 (MUC1-derived antigens) supports monitoring of breast cancer treatment response and detecting recurrence, similar in role to CEA in colorectal cancer, but these markers are not sensitive or specific enough for screening or initial diagnosis.

Diagnosis & clinical testing

Measured via serum immunoassay; like other tumor markers in this list, MUC1-derived antigens are used mainly for serial monitoring during and after treatment rather than as a diagnostic or screening test.

Guiding treatment

Rising CA 15-3/CA 27.29 during breast cancer surveillance prompts further workup (imaging) for possible recurrence or metastasis, always interpreted alongside clinical and radiologic findings rather than in isolation.

Clinical significance

Follows the same monitoring-only role pattern as CEA in colorectal cancer and CA 19-9 in pancreatic cancer.

References
  1. General oncology reference literature on CA 15-3/CA 27.29 in breast cancer monitoring.